Q BioMed Inc.
QBIO · OTC
2/28/2023 | 11/30/2022 | 8/31/2022 | 5/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.01 | 0.01 |
| FCF Yield | -10.59% | 371.93% | -18.38% | -3.06% |
| EV / EBITDA | -12.40 | -8.64 | -9.09 | -8.69 |
| Quality | ||||
| ROIC | 21.62% | -508.80% | 22.96% | 25.42% |
| Gross Margin | 0.00% | -539.82% | -152.91% | 57.33% |
| Cash Conversion Ratio | 0.19 | 1.16 | 0.30 | 0.09 |
| Growth | ||||
| Revenue 3-Year CAGR | 44.23% | 111.63% | 132.44% | 197.80% |
| Free Cash Flow Growth | -105.18% | 1,214.57% | -117.55% | 70.81% |
| Safety | ||||
| Net Debt / EBITDA | -9.39 | -7.34 | -6.69 | -4.21 |
| Interest Coverage | -1.61 | 9.34 | -3.25 | -2.06 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -5,511,439,473,180,672.00 | 2.93 | 3.24 |
| Cash Conversion Cycle | -81,094.28 | -2,309.71 | -2,746.79 | -2,347.57 |